Alzheimer’s Patient Newsletter February 2020
Aducanumab, the first Alzheimer’s-modifying therapy, submitted to the FDA. Can Biogen recover from their errors?
Alzheimer’s Patient Newsletter February 2020 Read More »
Aducanumab, the first Alzheimer’s-modifying therapy, submitted to the FDA. Can Biogen recover from their errors?
Alzheimer’s Patient Newsletter February 2020 Read More »
“If you have a loved one with dementia, you know this can be a heart-wrenching process. You cannot change the person. . . . You have to meet them where they are, roll with it, and speak with love and patience. It was a pleasure to speak to Dr. David Weisman, a neurologist.”
Dr. Weisman interviewed on Boomer Living podcast Read More »
The field of MS research has had amazing success in the last two decades.
MS Patient Newsletter December 2019 Read More »
Multiple sclerosis (MS) is an autoimmune disease in which the immune system misrecognizes part of the brain called myelin.
MS Physician Newsletter October 2019 Read More »
Early on in their careers, two neurologists became involved in advocacy issues on behalf of neurology on a national, regional, and local level.
Dr. Klein featured in Neurology Today Read More »
One day, one of the trials in Alzheimer’s disease will be positive. We think this trial may already be underway.
Alzheimer’s Patient Newsletter July 2019 Read More »
Dr. Klein has been appointed Chair of the Medical Economics and Practice committee, as well as serving on the Board of Directors.
Dr. Klein named to the AAN Board of Directors Read More »
We continue to fight for a disease modifying treatment in Alzheimer’s disease despite recent setbacks.
Alzheimer’s Physician Newsletter May 2019 Read More »
Dr. Klein has published an editorial opposing a well-intentioned but overbearing new law proposed by the Philadelphia City Council.
Dr. Klein publishes Op Ed in The Inquirer Read More »
The FDA recently allowed 23andMe to release health risk info to customers. “This is a travesty,” he said in an interview.
Dr. Weisman quoted in Philadelphia Inquirer article about genetic testing Read More »